Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma

August 1st 2025

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma

August 1st 2025

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

Asciminib Nets Canadian Approval in Newly Diagnosed and Previously Treated Ph+ CML

July 31st 2025

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Hemoglobin Improvement With Momelotinib Confers OS Benefit in Myelofibrosis With Anemia

July 31st 2025

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

Addressing Further Unmet Needs in PNH

July 30th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss unmet needs to address in the management of PNH.

Implications of APPULSE-PNH Data for Iptacopan in PNH

July 30th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss implications of data from the APPULSE-PNH trial of iptacopan.

IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML

July 29th 2025

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

IHC Testing May Bridge Gaps With NGS for Early Identification, Intervention in TP53-Mutant MDS and AML

July 28th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

FDA Approves Generic Ibrutinib Tablets for B-Cell Malignancies

July 24th 2025

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

FDA Grants Priority Review to Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 24th 2025

Tabelecleucel earned FDA priority review for EBV-positive post-transplant lymphoproliferative disease following a January 2025 complete response letter.

IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML

July 24th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH

July 23rd 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, detail factors for selecting iptacopan in C5 inhibitor–naive and –exposed PNH.

Natural Language Processing Streamlines Clinical Encounter Note Collection in Indolent Systemic Mastocytosis

July 23rd 2025

Natural language processing models could help streamline processes within clinical settings.

Dr Luminari on the Safety Profile of Odronextamab in Relapsed/Refractory Follicular Lymphoma

July 22nd 2025

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment

July 22nd 2025

The oral formulation of decitabine-cedazuridine helps empower patients with MDS or CMML to maintain their quality of life from the comfort of their home.

European Commission Approves Obe-Cel for Adult R/R B-Cell Precursor Acute Lymphoblastic Leukemia

July 21st 2025

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

July 18th 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.